In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment

(2009) Marcin Kortylewski et al.   CANCER CELL

gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated Tumorigenesis

(2009) Julia Bollrath et al.   CANCER CELL

Persistently Activated Stat3 Maintains Constitutive NF-κB Activity in Tumors

(2009) Heehyoung Lee et al.   CANCER CELL

IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer

(2009) Sergei Grivennikov et al.   CANCER CELL

Toll-like Receptor 9 Activation of Signal Transducer and Activator of Transcription 3 Constrains Its Agonist-Based Immunotherapy

(2009) M. Kortylewski et al.   CANCER RESEARCH

IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway

(2009) Lin Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Role of Stat3 in suppressing anti-tumor immunity

(2008) Marcin Kortylewski et al.   CURRENT OPINION IN IMMUNOLOGY

Accessing the therapeutic potential of immunostimulatory nucleic acids

(2008) Winfried Barchet et al.   CURRENT OPINION IN IMMUNOLOGY

Stat3 mediates myeloid cell–dependent tumor angiogenesis in mice

(2008) Maciej Kujawski et al.   JOURNAL OF CLINICAL INVESTIGATION

Synthetic oligonucleotides as modulators of inflammation

(2008) Dennis Klinman et al.   JOURNAL OF LEUKOCYTE BIOLOGY

5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

(2008) Hendrik Poeck et al.   NATURE MEDICINE

Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies

(2008) D E Spaner et al.   ONCOGENE

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE